Differentiating between type 1 and type 2 amiodarone-induced thyrotoxicosis is crucial for guiding appropriate medical therapy with thionamides, potassium perchlorate, or glucocorticoids.
No takes yet. Share an insight, caveat, or question.
Warrants routine thyroid monitoring with amiodarone; leaves open standardized type 1 versus type 2 differentiation protocols.
Bogazzi et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: